调研速递|汉森制药接受投资者网上提问调研，聚焦三湘银行股权与康普药业并购问题

Core Viewpoint - The performance briefing held by Hunan Hansen Pharmaceutical Co., Ltd. focused on two main issues: the financial loss from investing in Sanxiang Bank and potential acquisition plans for Kangpu Pharmaceutical [1] Group 1: Financial Performance and Strategic Investments - The company acknowledged financial losses due to its investment in Sanxiang Bank, which is part of its "one body, two wings" development strategy aimed at maintaining its core traditional Chinese medicine business while expanding into the health industry and integrating financial services [1] - The company committed to timely information disclosure regarding any significant matters related to the transfer of its stake in Sanxiang Bank [1] Group 2: Potential Mergers and Acquisitions - Investors inquired about the possibility of acquiring Kangpu Pharmaceutical, in which the controlling shareholder Liu Ling'an increased his stake in 2021 [1] - The company stated that it would also disclose any future merger and acquisition activities in a timely manner [1] Group 3: Investor Communication - The performance briefing allowed direct communication between investors and the company's management, highlighting the company's commitment to transparency and timely information disclosure regarding strategic investments and potential acquisitions [1]